Skip to content

Embrace: Seizure Characterization

Characterizing Sleep, Stress, and Seizures in Daily Life: An Internet-based Study With the Empatica Embrace Watch and Smartphone-based Diary-alert System

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03206502
Enrollment
100000
Registered
2017-07-02
Start date
2016-05-31
Completion date
2026-05-31
Last updated
2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Brief summary

The study is intended to characterize sleep, stress, and seizures in daily life with the Empatica Embrace watch and smartphone-based diary-alert system. The primary study objective is to collect and validate biometric signals from epilepsy patients using the Empatica Embrace watch and compare them to ictal events captured from human (patient and caregiver) reports.

Detailed description

Patients use the Embrace sensor with a smartphone app, Alert. The sensor attempts to capture convulsive seizure events such as generalized tonic-clonic seizures (GTCS's), and to initiate an alert when such an event is captured. Patients can also enter seizures (captured or not, GTCS or not) into the Mate diary, and they can cancel or mark false alarms if Embrace triggered a false alarm.

Interventions

DEVICEEmbrace + Alert App

Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.

Sponsors

Empatica, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants must be between the ages of 1-99 * Anyone (healthy or not) can participate * Adult participant must either be able to give consent or must have an acceptable surrogate capable of giving consent on their behalf. * Participants under age 18 must have an adult guardian give informed consent, and if capable, the patient must give informed assent. * Participants with GTCS must have a functioning smartphone (iOS or Android) that can be paired with the Embrace over a Bluetooth Low Energy connection and agree that it can be kept on or near their person. * Participants with GTCS (or their surrogate) must be able to identify one or more designated frequent caregivers, who has a functioning phone, agrees to keep it regularly charged, agrees to receive alerts, and agrees to respond to alerts promptly to the best of their ability. * Participants must be fluent in the language of the consent forms (Currently limited to English but Spanish and other languages are planned). * Participants must reside in the United States.

Exclusion criteria

* Participants must not have broken or injured skin at the wrist or leg location where Embrace is worn, and they must be able to tolerate wearing Embrace snugly for long periods of time. Thus, they should not have allergies to the material composition of the Embrace watch, or discomfort wearing a wristwatch or leg-band device. * Participants should not be homeless. * Participants should not have active dependence on substances that are not currently prescribed by their doctor (e.g. alcohol, pain medications, illegal drugs) or be taking substances that they are not willing to disclose as a study participant. * Participants must not be pregnant or planning to become pregnant within six months at the time of screening.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of the GTCS detection of the Embrace + Alert appThe primary outcome is assessed continuously over the trial period (each new seizure is counted and summed for each person; the average time period is 6 months)The number of GTCS automatically detected by Embrace will be compared to the total recorded by the wearer+caregiver in a seizure diary. This fraction is the sensitivity.

Secondary

MeasureTime frameDescription
False alarm rate of the GTCS detection of the Embrace + Alert appThe secondary outcome is assessed continuously over the trial period (each false alarm is counted and summed for a running total within each person; the average time period is 6 months)The number of alerts elicited by Embrace+Alert app that do NOT correspond to convulsive seizures marked in the seizure diary are false alarms. False alarms can also be explicitly marked by patients.

Other

MeasureTime frameDescription
System UsabilityAfter one month of use.The System Usability Scale will be given to assess system usability

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026